A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
A Phase Ib/II, Multicenter Open-label Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
Sponsor: Bayer
Listed as NCT04200404, this PHASE1/PHASE2 trial focuses on Advanced Refractory Solid Tumors and remains completed. Sponsored by Bayer, it has been updated 7 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
Jan 2021 — Jun 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 2 earlier versions
-
Feb 2020 — Oct 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Dec 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- CStone Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .